Seattle-based startup RareCyte announced $24 million in new funding on Thursday to advance its applications for the analysis of cells. RareCyte sells imaging-based liquid and tissue biopsy analysis platforms that… Read More
A liquid biopsy sounds like far-future tech: It’s essentially a blood test that can detect cancer by analyzing DNA from dead tumor cells that floats in a patient’s bloodstream. These… Read More